The transcriptional upregulation of oncogenes is a driving force behind the progression of
many tumours. However, until a decade ago, the concept of 'switching off'these oncogenic …

Epigenetic drug discovery field has evidenced significant advancement in the recent times.
A plethora of small molecule inhibitors have progressed to clinical stage investigations and …

Epigenetics has been defined as 'the structural adaptation of chromosomal regions so as to
register, signal or perpetuate altered activity states.'Currently, several classes of anticancer …

There is an urgent need to identify novel therapies for childhood cancers. Neuroblastoma is
the most common pediatric solid tumor, and accounts for~ 15% of childhood cancer‐related …

Neuroblastoma is the most common extra-cranial solid tumor of childhood and the most
common in the first year of life. It is a unique malignancy in that infants often present with …

Extrachromosomal DNA (ecDNA) is prevalent in human cancers and mediates high
expression of oncogenes through gene amplification and altered gene regulation. Gene …

Enhanced and deregulated expression of N-MYC, a member of the MYC family of
transcription factors, drives the development of multiple tumors, including tumors of the …

Several cancer clinical trials for small molecule inhibitors of BET bromodomain proteins
have been initiated. There is enthusiasm for the anti-proliferative effect of inhibiting BRD4 …

NUT carcinoma (NC) is a rare, aggressive subtype of squamous cell carcinoma defined by
rearrangement of the NUTM1 (aka NUT) gene. NC is driven by NUT‐fusion oncoproteins …

Spinal ependymal tumors form a histologically and molecularly heterogeneous group of
tumors with generally good prognosis. However, their treatment can be challenging if …